Catalent CEO to remain in charge of contract drugmaker
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
Catalent’s Maselli to continue as CEO post Novo Holdings deal close
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli said,
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 billion deal will not raise competitive concerns.
Catalent issues letter to customers regarding acquisition by Novo Holdings
Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
US Senator Warren Calls for Scrutiny of Novo Holdings' Catalent Deal
NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent, saying it may give the pharmaceutical company an unlawful advantage in obesity drugs.
FierceBiotech6h
AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinic
AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...
STAT4d
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...
FierceBiotech12d
Novo Holdings-backed Booster takes off with protein degraders aimed at neurodegeneration
Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...
Catalent Issues Open Letter To Customers; To Operate As Full-service CDMO Under Novo
Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will ...
Whittier Trust Co. Acquires 1,115 Shares of Novo Nordisk A/S (NYSE:NVO)
Whittier Trust Co. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...